836 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using a Highly Branched Poly(β-Amino Ester) Polymer (HPAE-EB)

I. Lara-Saez,L. Cutlar,D. Zhou,J. O'Keeffe Ahern,M. Zeng,F. Larcher,W. Wang
DOI: https://doi.org/10.1016/j.jid.2018.03.846
2018-01-01
Abstract:RDEB is one of the most severe subtypes of EB, caused by mutations in COL7A1, which encodes for type VII collagen (C7), defined by fragility of the skin and epithelial tissues. The 8.9Kb COL7A1 transcript is a particularly large sequence with many repeating units which makes it difficult to manipulate and package into viral systems. Among non-viral delivery systems, cationic polymer vectors offer significant advantages over virus’ owing to their ability to condense DNA into nanoparticles. HPAE-EB is a cationic polymer, which binds electrostatically with negatively charged DNA (COL7a1) to form nanoscale polyplexes. In vitro studies revealed that HPAE-EB+COL7A1 polyplexes are well tolerated by healthy primary human and RDEB keratinocytes and more efficient at delivery compared to commercial vectors. Safety studies in SKH1 mice did not show any toxicology difference between the application of the controls (untreated and buffer) and HPAE-EB+COL7A1 polyplexes or HPAE-EB alone in a single intravenous dose (n=3) or multiple intradermal doses (n=11). Polyplexes made with PEI (positive control for toxicity) were irritant and caused skin damage, no negative effects were seen after injection of the HPAE-EB+COL7A1 polyplexes. Thus far a pilot study has begun using a human RDEB graft mouse model (n=5) to assess the efficiency of multiple topical applications with further comprehensive analysis to evaluate long term C7 expression. HPAE-EB+COL7A1 polyplexes show great promise as a potential topical therapeutic for treating the as of yet incurable RDEB, in addition to being gentle on the skin thereby adding any additional pain to the patients. Moreover this non-viral gene delivery system has broad spectrum applicability and can be used as a platform delivery system for other monogenic disorders.
What problem does this paper attempt to address?